2603.00099 Executable cross-cohort benchmarking of NSCLC immunotherapy biomarkers reveals robust transfer of tumor mutational burden
Reliable biomarkers for immune checkpoint therapy in non-small-cell lung cancer (NSCLC) remain difficult to validate across cohorts and treatment regimens. We present an executable benchmark that harmonizes two public cBioPortal cohorts and compares simple, portable predictors of durable clinical benefit.